The Safety of Novel Therapies in Chronic Lymphocytic Leukemia in the Era of Intermittent Fasting: A Pharmacology-Based Review

<p dir="ltr">Intermittent fasting (IF) has recently gained popularity due to its emerging benefits in reducing weight and improving metabolic health. Concurrently, novel agents (NAs) like venetoclax and Bruton tyrosine kinase inhibitors (BTKIs) have revolutionized the treatment of ch...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Maria Benkhadra (19756941) (author)
مؤلفون آخرون: Nuha Fituri (19756944) (author), Soha Aboukhalaf (19756947) (author), Rola Ghasoub (16555851) (author), Mervat Mattar (17430972) (author), Khalil Alfarsi (17430975) (author), Salem Alshemmari (19756950) (author), Mohamed A. Yassin (8361183) (author)
منشور في: 2024
الموضوعات:
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة